<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39207089</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1600-0625</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Experimental dermatology</Title><ISOAbbreviation>Exp Dermatol</ISOAbbreviation></Journal><ArticleTitle>Treatment of malignant melanoma with coxsackievirus A21 (V937): An emerging oncolytic virotherapy.</ArticleTitle><Pagination><StartPage>e15169</StartPage><MedlinePgn>e15169</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/exd.15169</ELocationID><Abstract><AbstractText>Despite rising melanoma incidence in recent decades, there is a trend towards overall decreased mortality, reflecting multiple factors including improved treatment options for metastatic disease. While local treatments are the mainstay for early-stage melanoma, metastatic disease necessitates systemic treatment, with oncolytic virotherapy emerging as a promising option. For this review, articles were retrieved from PubMed from 1964 through 2024. We conducted title, abstract and full-text screening in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to identify articles describing the use of coxsackievirus A21 (V937), either as monotherapy or as part of combination therapy for malignant melanoma. Fifteen articles met inclusion criteria, offering preclinical and clinical data on V937's efficacy in reducing tumour burden. In addition to reporting manageable safety profiles, clinical trial data examining intratumoral V937 combination therapy with pembrolizumab and ipilimumab also endorsed favourable objective response rates compared to immune checkpoint inhibitor monotherapy (47% vs. 38% and 21% vs. 10%, respectively). In contrast, intravenous V937 monotherapy failed to yield additional benefit in a cohort of patients with Stage IIIC/IV melanoma (n = 3) despite achieving detectable levels in tumour tissue (1 × 10<sup>9</sup> TCID<sub>50</sub>). Although small subsets of patients experienced severe adverse effects and study design limitations imposed constraints on collected data, evidence for the efficacy of V937 remains encouraging. With few clinical trials evaluating V937 in melanoma, additional data is required before routine usage in standard treatment for metastatic lesions.</AbstractText><CopyrightInformation>© 2024 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sakunchotpanit</LastName><ForeName>Goranit</ForeName><Initials>G</Initials><Identifier Source="ORCID">0009-0006-2125-0860</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts University School of Medicine, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Mihir K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0001-6423-1746</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Carle Illinois College of Medicine, Urbana, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Kaushik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohan</LastName><ForeName>Thomas Z</ForeName><Initials>TZ</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Debby</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nambudiri</LastName><ForeName>Vinod E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Exp Dermatol</MedlineTA><NlmUniqueID>9301549</NlmUniqueID><ISSNLinking>0906-6705</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074324">Ipilimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>DPT0O3T46P</RegistryNumber><NameOfSubstance UI="C582435">pembrolizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050130" MajorTopicYN="Y">Oncolytic Virotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="Y">Melanoma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="Y">Skin Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074324" MajorTopicYN="N">Ipilimumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="N">Oncolytic Viruses</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coxsackievirus</Keyword><Keyword MajorTopicYN="N">ipilimumab</Keyword><Keyword MajorTopicYN="N">melanoma</Keyword><Keyword MajorTopicYN="N">oncolytic</Keyword><Keyword MajorTopicYN="N">pembrolizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>1</Day><Hour>16</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>8</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39207089</ArticleId><ArticleId IdType="doi">10.1111/exd.15169</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17‐48. doi:10.3322/caac.21763</Citation></Reference><Reference><Citation>Ziogas DC, Martinos A, Petsiou DP, Anastasopoulou A, Gogas H. Beyond immunotherapy: seizing the momentum of oncolytic viruses in the ideal platform of skin cancers. Cancer. 2022;14(12):2873. doi:10.3390/cancers14122873</Citation></Reference><Reference><Citation>Barker CA, Lee NY. Radiation therapy for cutaneous melanoma. Dermatol Clin. 2012;30(3):525‐533. doi:10.1016/j.det.2012.04.011</Citation></Reference><Reference><Citation>Mullick N, Nambudiri VE. Relatlimab–nivolumab: a practical overview for dermatologists. J Am Acad Dermatol. 2023;89(5):1031‐1037. doi:10.1016/j.jaad.2023.06.024</Citation></Reference><Reference><Citation>Chesney JA, Ribas A, Long GV, et al. Randomized, double‐blind, placebo‐controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol. 2023;41(3):528‐540. doi:10.1200/jco.22.00343</Citation></Reference><Reference><Citation>Goldufsky J, Sivendran S, Harcharik S, et al. Oncolytic virus therapy for cancer. Oncolytic Virother. 2013;2:31‐46. doi:10.2147/ov.S38901</Citation></Reference><Reference><Citation>Buijs PR, Verhagen JH, van Eijck CH, van den Hoogen BG. Oncolytic viruses: from bench to bedside with a focus on safety. Hum Vaccin Immunother. 2015;11(7):1573‐1584. doi:10.1080/21645515.2015.1037058</Citation></Reference><Reference><Citation>Hromic‐Jahjefendic A, Lundstrom K. Viral vector‐based melanoma gene therapy. Biomedicine. 2020;8(3): 60. 10.3390/biomedicines8030060</Citation></Reference><Reference><Citation>Hersey P, Gallagher S. Intralesional immunotherapy for melanoma. J Surg Oncol. 2014;109(4):320‐326. doi:10.1002/jso.23494</Citation></Reference><Reference><Citation>Annels NE, Arif M, Simpson GR, et al. Oncolytic immunotherapy for bladder cancer using coxsackie A21 virus. Mol Ther Oncolytics. 2018;9:1‐12. doi:10.1016/j.omto.2018.02.001</Citation></Reference><Reference><Citation>Lundstrom K. New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy. Biologics. 2018;12:43‐60. doi:10.2147/btt.S140114</Citation></Reference><Reference><Citation>Silk AW, O'Day SJ, Kaufman HL, et al. A phase 1b single‐arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study. Cancer Immunol Immunother. 2023;72(6):1405‐1415. doi:10.1007/s00262-022-03314-1</Citation></Reference><Reference><Citation>Relph K, Arif M, Pandha H, Annels N, Simpson GR. Analysis of ICAM‐1 expression on bladder carcinoma cell lines and infectivity and oncolysis by coxsackie virus A21. Methods Mol Biol. 2023;2684:319‐327. doi:10.1007/978-1-0716-3291-8_20</Citation></Reference><Reference><Citation>Berry LJ, Au GG, Barry RD, Shafren DR. Potent oncolytic activity of human enteroviruses against human prostate cancer. Prostate. 2008;68(6):577‐587. doi:10.1002/pros.20741</Citation></Reference><Reference><Citation>Skelding KA, Barry RD, Shafren DR. Systemic targeting of metastatic human breast tumor xenografts by coxsackievirus A21. Breast Cancer Res Treat. 2009;113(1):21‐30. doi:10.1007/s10549-008-9899-2</Citation></Reference><Reference><Citation>Au GG, Lindberg AM, Barry RD, Shafren DR. Oncolysis of vascular malignant human melanoma tumors by coxsackievirus A21. Int J Oncol. 2005;26(6):1471‐1476. doi:10.3892/ijo.26.6.1471</Citation></Reference><Reference><Citation>Shafren DR, Au GG, Nguyen T, et al. Systemic therapy of malignant human melanoma tumors by a common cold‐producing enterovirus, coxsackievirus A21. Clin Cancer Res. 2004;10(1 Pt 1):53‐60. doi:10.1158/1078-0432.ccr-0690-3</Citation></Reference><Reference><Citation>Curti BD, Richards J, Hyngstrom JR, et al. Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study. J Immunother Cancer. 2022;10(12):e005224. doi:10.1136/jitc-2022-005224</Citation></Reference><Reference><Citation>Rudin CM, Pandha HS, Zibelman M, et al. Phase 1, open‐label, dose‐escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. J Immunother Cancer. 2023;11(1):e005007. doi:10.1136/jitc-2022-005007</Citation></Reference><Reference><Citation>Andtbacka RHI, Curti B, Daniels GA, et al. Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma. J Clin Oncol. 2021;39(34):3829‐3838. doi:10.1200/jco.20.03246</Citation></Reference><Reference><Citation>Katta B, Vijayakumar C, Dutta S, Dubashi B, Nelamangala Ramakrishnaiah VP. The incidence and severity of patient‐reported side effects of chemotherapy in routine clinical care: a prospective observational study. Cureus. 2023;15(4):e38301. doi:10.7759/cureus.38301</Citation></Reference><Reference><Citation>Lutzky J, Sullivan RJ, Cohen JV, Ren Y, Li A, Haq R. Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma. J Cancer Res Clin Oncol. 2023;149(9):6059‐6066. doi:10.1007/s00432-022-04510-3</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>